378 related articles for article (PubMed ID: 30666822)
21. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
22. Engineered nanomedicines to overcome resistance of pancreatic cancer to immunotherapy.
Elzoghby AO; Ferrone CR; Ferrone S; Nasr ML
Drug Discov Today; 2023 Jan; 28(1):103434. PubMed ID: 36368630
[TBL] [Abstract][Full Text] [Related]
23. Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy.
Zhong XF; Sun X
Acta Pharmacol Sin; 2020 Jul; 41(7):928-935. PubMed ID: 32355277
[TBL] [Abstract][Full Text] [Related]
24. Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines.
García-Fernández C; Saz A; Fornaguera C; Borrós S
Cancer Gene Ther; 2021 Sep; 28(9):935-946. PubMed ID: 33837365
[TBL] [Abstract][Full Text] [Related]
25. Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.
Fang RH; Kroll AV; Zhang L
Small; 2015 Nov; 11(41):5483-96. PubMed ID: 26331993
[TBL] [Abstract][Full Text] [Related]
26. Stimuli-Sheddable Nanomedicine Overcoming Pathophysiological Barriers for Potentiating Immunotherapy of Cancer.
Wang J; Zhou M; Chen F; Liu X; Gao J; Wang W; Wang H; Yu H
J Biomed Nanotechnol; 2021 Aug; 17(8):1486-1509. PubMed ID: 34544528
[TBL] [Abstract][Full Text] [Related]
27. Cancer Nanomedicine: Lessons for Immuno-Oncology.
Sengupta S
Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
[TBL] [Abstract][Full Text] [Related]
28. Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.
Wang C; Ye Y; Hu Q; Bellotti A; Gu Z
Adv Mater; 2017 Aug; 29(29):. PubMed ID: 28556553
[TBL] [Abstract][Full Text] [Related]
29. Cancer nanomedicine meets immunotherapy: opportunities and challenges.
Sun Q; Bai X; Sofias AM; van der Meel R; Ruiz-Hernandez E; Storm G; Hennink WE; De Geest B; Kiessling F; Yu HJ; Lammers T; Shi Y
Acta Pharmacol Sin; 2020 Jul; 41(7):954-958. PubMed ID: 32555445
[TBL] [Abstract][Full Text] [Related]
30. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
Martin JD; Cabral H; Stylianopoulos T; Jain RK
Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
[TBL] [Abstract][Full Text] [Related]
31. [Recent advances and future challenges in cancer immunotherapy].
Okuyama N; Tamada K; Tamura H
Rinsho Ketsueki; 2016; 57(11):2388-2395. PubMed ID: 27941290
[TBL] [Abstract][Full Text] [Related]
32. Polymeric Micelles in Cancer Immunotherapy.
Wan Z; Zheng R; Moharil P; Liu Y; Chen J; Sun R; Song X; Ao Q
Molecules; 2021 Feb; 26(5):. PubMed ID: 33668746
[TBL] [Abstract][Full Text] [Related]
33. Role of Clinical Pharmacology in the Development and Approval of Immunotherapies Targeting Immune Checkpoints.
Rahman A
Clin Pharmacol Ther; 2016 Dec; 100(6):591-593. PubMed ID: 27500894
[TBL] [Abstract][Full Text] [Related]
34. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy.
Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z
Small; 2017 Oct; 13(40):. PubMed ID: 28861943
[TBL] [Abstract][Full Text] [Related]
35. Nanomedicines Targeting the Tumor Microenvironment.
Tong R; Langer R
Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
[TBL] [Abstract][Full Text] [Related]
36. In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.
Sheen MR; Fiering S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1524. PubMed ID: 29667346
[TBL] [Abstract][Full Text] [Related]
37. Tumor immunotherapy: the tumor cell as an antigen-presenting cell.
Ostrand-Rosenberg S
Curr Opin Immunol; 1994 Oct; 6(5):722-7. PubMed ID: 7826527
[TBL] [Abstract][Full Text] [Related]
38. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
Li W; Peng A; Wu H; Quan Y; Li Y; Lu L; Cui M
Front Immunol; 2020; 11():601497. PubMed ID: 33408716
[TBL] [Abstract][Full Text] [Related]
39. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
Corrales L; Gajewski TF
Cytokine; 2016 Jan; 77():245-7. PubMed ID: 26315534
[No Abstract] [Full Text] [Related]
40. T cell recognition of human tumors: implications for molecular immunotherapy of cancer.
Ioannides CG; Whiteside TL
Clin Immunol Immunopathol; 1993 Feb; 66(2):91-106. PubMed ID: 8453790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
